Brokers Issue Forecasts for Immunic FY2026 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at William Blair issued their FY2026 earnings estimates for Immunic in a research note issued on Monday, March 24th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.98) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

IMUX has been the topic of a number of other reports. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Immunic currently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $1.20 on Thursday. The firm has a market cap of $108.09 million, a price-to-earnings ratio of -0.98 and a beta of 1.89. The stock’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares in the last quarter. State Street Corp raised its holdings in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Immunic during the third quarter worth about $50,000. Finally, HB Wealth Management LLC bought a new position in Immunic in the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.